Bottle
Latest Novartis AG Patents:
- Tricyclic AKR1C3 dependent KARS inhibitors
- Treatment of cancer using GFR alpha-4 chimeric antigen receptor
- Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins
- Solid forms comprising an oxime ether compound, compositions and methods of use thereof
- Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
The broken line showing of the bottle is included for the purpose of illustrating portions of the bottle and forms no part of the claimed design.
Claims
The ornamental design for a bottle, as shown and described.
D315409 | March 12, 1991 | Baarber |
D353518 | December 20, 1994 | Cautereels et al. |
D412085 | July 20, 1999 | Roush et al. |
D412281 | July 27, 1999 | Lindsay et al. |
D434273 | November 28, 2000 | Johansen et al. |
D445033 | July 17, 2001 | Bretz et al. |
D456714 | May 7, 2002 | Brauner et al. |
D466813 | December 10, 2002 | Thierjung et al. |
D466819 | December 10, 2002 | Darr et al. |
D467179 | December 17, 2002 | Nelson et al. |
6513379 | February 4, 2003 | Meyers et al. |
D475890 | June 17, 2003 | Mazonkey |
D479999 | September 30, 2003 | Moore |
D504063 | April 19, 2005 | Bretz et al. |
D506139 | June 14, 2005 | Zboch et al. |
20020070193 | June 13, 2002 | Mero |
20040155008 | August 12, 2004 | Lane et al. |
20040200799 | October 14, 2004 | Yourist et al. |
20060157439 | July 20, 2006 | Howell |
000403969-0001 | December 2005 | EM |
000403969-0003 | December 2005 | EM |
2084672 | April 1999 | GB |
Type: Grant
Filed: Jun 28, 2005
Date of Patent: Aug 7, 2007
Assignee: Novartis AG (Basel)
Inventor: John Wolf (Spring Lake, MI)
Primary Examiner: Mitchell Siegel
Assistant Examiner: Keli L. Acker
Attorney: Mekalaradha Masilamani
Application Number: 29/233,074